Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR) released its quarterly earnings results on Tuesday. The biopharmaceutical company reported ($0.92) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.21) by $0.29, Bloomberg Earnings reports. During the same quarter last year, the firm earned ($0.70) EPS.

Alder BioPharmaceuticals (NASDAQ ALDR) opened at $10.70 on Wednesday. Alder BioPharmaceuticals has a 1-year low of $8.60 and a 1-year high of $34.30.

In related news, insider Mark James Litton sold 16,520 shares of the firm’s stock in a transaction that occurred on Monday, October 16th. The shares were sold at an average price of $12.33, for a total value of $203,691.60. Following the transaction, the insider now owns 116,452 shares in the company, valued at $1,435,853.16. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Company insiders own 10.60% of the company’s stock.

ALDR has been the topic of several analyst reports. Zacks Investment Research raised shares of Alder BioPharmaceuticals from a “hold” rating to a “buy” rating and set a $13.00 price target on the stock in a research note on Tuesday, July 11th. ValuEngine raised shares of Alder BioPharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Saturday, September 30th. Cowen and Company assumed coverage on shares of Alder BioPharmaceuticals in a research note on Tuesday, September 26th. They set an “outperform” rating and a $20.00 price target on the stock. Mizuho reissued a “buy” rating and issued a $32.00 target price on shares of Alder BioPharmaceuticals in a research report on Friday, September 15th. Finally, Royal Bank Of Canada assumed coverage on shares of Alder BioPharmaceuticals in a research report on Thursday, September 14th. They issued an “outperform” rating and a $17.00 target price on the stock. Three equities research analysts have rated the stock with a sell rating, two have issued a hold rating and eleven have issued a buy rating to the stock. Alder BioPharmaceuticals currently has a consensus rating of “Buy” and an average target price of $28.07.

TRADEMARK VIOLATION NOTICE: “Alder BioPharmaceuticals, Inc. (ALDR) Releases Quarterly Earnings Results” was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this article on another domain, it was stolen and reposted in violation of U.S. and international trademark and copyright laws. The correct version of this article can be viewed at

Alder BioPharmaceuticals Company Profile

Alder BioPharmaceuticals, Inc, is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize genetically engineered therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. Alder’s lead pivotal-stage product candidate, eptinezumab, is being evaluated for migraine prevention.

Earnings History for Alder BioPharmaceuticals (NASDAQ:ALDR)

Receive News & Stock Ratings for Alder BioPharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alder BioPharmaceuticals Inc. and related stocks with our FREE daily email newsletter.